Thiazide diuretics and statins are used to improve cardiovascular outcomes, but 
may also cause type 2 diabetes (T2DM), although mechanisms are unknown. Gene 
expression studies may facilitate understanding of these associations. 
Participants from ongoing population-based studies were sampled for these 
longitudinal studies of peripheral blood microarray gene expression, and 
followed to incident diabetes. All sampled subjects were statin or thiazide 
users. Those who developed diabetes during follow-up comprised cases (44 
thiazide users; 19 statin users), and were matched to drug-using controls who 
did not develop diabetes on several factors. Supervised normalization, surrogate 
variable analyses removed technical bias and confounding. 
Differentially-expressed genes were those with a false discovery rate 
Q-value<0.05. Among thiazide users, diabetes cases had significantly different 
expression of CCL14 (down-regulated 6%, Q-value=0.0257), compared with controls. 
Among statin users, diabetes cases had marginal but insignificantly different 
expression of ZNF532 (up-regulated 15%, Q-value=0.0584), CXORF21 (up-regulated 
11%, Q-value=0.0584), and ZNHIT3 (up-regulated 19%, Q-value=0.0959), compared 
with controls. These genes comprise potential targets for future expression or 
mechanistic research on medication-related diabetes development.